Method for evaluating the smoking index and its use in the treatment and evaluation of bladder cancer
By constructing a smoker index model and utilizing CGB5 inhibitors and detection kits, the challenges of assessing the prognosis and survival rate of bladder cancer have been solved, enabling precise treatment and prevention for bladder cancer patients.
CN115998755BActive Publication Date: 2026-04-14MACAU UNIV OF SCI & TECH
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202310138043.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-20
- Publication Date
- 2026-04-14
- Estimated Expiration
- 2043-02-20
AI Technical Summary
Technical Problem
The relationship between smoking and bladder cancer prognosis and survival rate is unclear in the current technology, making it difficult to effectively prevent and assess it.
Method used
A kit for evaluating a smoker index is provided, which constructs a smoker index model by detecting CGB5 expression levels and other biomarkers to predict bladder cancer risk and survival. The kit includes a CGB5 inhibitor, a reagent for detecting CGB5 expression levels, and a method for evaluating the smoker index.
Benefits of technology
It can accurately assess the prognosis and survival rate of bladder cancer patients, screen high-risk groups, provide personalized treatment plans, and significantly reduce the probability and severity of the disease.
✦ Generated by Eureka AI based on patent content.
Abstract
The application provides a method for evaluating smoker index and application thereof in bladder cancer treatment and evaluation. The application has carried out in-depth research on the pathogenesis and development mechanism of bladder cancer, found that smoking is a risk factor highly correlated with bladder cancer, and constructed a quantifiable model-smoker index which can be used for system evaluation of the smoking state of patients, so that the prognosis and survival state of bladder cancer patients can be more accurately predicted and evaluated through analysis of the expression level of specific markers in the body of the subjects. The application clarifies the correlation between CGB5 and bladder cancer, and can effectively inhibit the proliferation, migration and other activities of bladder cancer cells by inhibiting the expression of CGB5. The application provides a new drug treatment target for human to conquer bladder cancer, thereby providing a new direction for subsequent drug research and development, clinical treatment and the like, and has very high social value and market application prospect.
Need to check novelty before this filing date? Find Prior Art